Home›Stock Screener›Venus Remedies›Intrinsic Value

Venus Remedies Intrinsic Value

Venus Remedies intrinsic value. Venus Remedies (VENUSREM) median intrinsic value is ₹1185.94 from 10 valuation models (range ₹450–₹1689), vs current price ₹1501.60 — -21.0% downside (Trading Above Calculated Value), margin of safety -26.6%. For current market price and key ratios, visit Venus Remedies share price screener.

Market Price (CMP)
₹1501.60
Primary Intrinsic Value
₹1688.72
Market Cap
₹1952 Cr
-21.0% Downside
Median Value
₹1185.94
Value Range
₹450 - ₹1689
Assessment
Trading Above Calculated Value
Safety Margin
-26.6%

VENUSREM Valuation Methods Summary — DCF, Graham Number & P/E

Venus Remedies intrinsic value across 10 models vs current price ₹1501.60 — upside/downside and value range per method. Analyse VENUSREM shareholding pattern to track promoter, FII and institutional holdings.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹1688.72 ₹1350.98 - ₹2026.46 +12.5% EPS: ₹76.76, Sector P/E: 22x
Book Value Method asset ₹1021.54 ₹919.39 - ₹1123.69 -32.0% Book Value/Share: ₹510.77, P/B: 2.0x
Revenue Multiple Method revenue ₹1347.69 ₹1212.92 - ₹1482.46 -10.2% Revenue/Share: ₹673.85, P/S: 2.0x
EBITDA Multiple Method earnings ₹1323.08 ₹1190.77 - ₹1455.39 -11.9% EBITDA: ₹172.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹1630.00 ₹1304.00 - ₹1956.00 +8.6% CF Growth: 15.0%, Discount: 15%
PEG Ratio Method growth ₹491.26 ₹442.13 - ₹540.39 -67.3% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹1185.94 ₹1067.35 - ₹1304.53 -21.0% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹1120.00 ₹1008.00 - ₹1232.00 -25.4% ROE: 15.7%, P/E Multiple: 14x
Graham Defensive Method conservative ₹939.23 ₹845.31 - ₹1033.15 -37.5% EPS: ₹76.76, BVPS: ₹510.77
Dividend Yield Method dividend ₹450.48 ₹405.43 - ₹495.53 -70.0% DPS: ₹10.00, Target Yield: 2.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

VENUSREM Intrinsic Value vs Market Price — All Valuation Models

Venus Remedies fair value range ₹450–₹1689 vs current market price ₹1501.60 across 10 valuation models. Browse VENUSREM cash flow statement for revenue, profit, balance sheet and cash flow data.

VENUSREM Intrinsic Value Analysis — Undervalued or Overvalued?

Venus Remedies median intrinsic value ₹1185.94, current price ₹1501.60 — Trading Above Calculated Value by 21.0%, margin of safety -26.6%.

What is the intrinsic value of VENUSREM?

Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Venus Remedies (VENUSREM) is ₹1185.94 (median value). With the current market price of ₹1501.60, this represents a -21.0% variance from our estimated fair value.

The valuation range spans from ₹450.48 to ₹1688.72, indicating ₹450.48 - ₹1688.72.

Is VENUSREM undervalued or overvalued?

Based on our multi-method analysis, Venus Remedies (VENUSREM) appears to be trading above calculated value by approximately 21.0%.

VENUSREM Financial Health — Key Ratios vs Industry Benchmarks

Venus Remedies financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 15.7% Industry Standard: 15%+ Above 15% Measures shareholder return efficiency
Operating Margin 19.0% Industry Standard: 20%+ Above 10% Indicates operational efficiency level
Asset Turnover Ratio 1.03x Industry Standard: 1.0x+ Above 1.0x Measures asset utilization efficiency

VENUSREM Cash Flow Quality — Operating & Free Cash Flow

Venus Remedies operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹156 Cr ₹64 Cr Positive Free Cash Flow 7/10
March 2025 ₹86 Cr ₹48 Cr Positive Free Cash Flow 8/10
March 2024 ₹37 Cr ₹33 Cr Positive Free Cash Flow 8/10
March 2023 ₹37 Cr ₹8 Cr Positive Free Cash Flow 7/10
March 2022 ₹41 Cr ₹33 Cr Positive Free Cash Flow 8/10